Mr. Kelly was the chairman of the 2015 Papal Visit Committee for NYC and is active in numerous philanthropic endeavors, including serving as Chairman of the Board of the Mother Cabrini Health Foundation, a trustee of the New York Presbyterian Hospital and of Boston College, and as a member of the finance council for the Archdiocese of New York.
“Despite industry advancements, there are limited therapeutic options for treating patients with epithelioid sarcoma who struggle with high rates of recurrence and toxicities associated with currently used therapies,” said Gary K. Schwartz, M.D., chief of hematology and oncology at Columbia University and NewYork-Presbyterian Hospital, deputy director of the Herbert Irving Comprehensive Cancer Center, professor of oncology at Columbia University Vagelos College of Physicians and Surgeons and an investigator in Epizyme’s Phase 2 trial. “The TAZVERIK data from the ES cohort in Epizyme’s Phase 2 trial support its potential to provide clinically meaningful and durable responses, and tolerability for ES patients. This approval of TAZVERIK represents an important advancement in the treatment of patients with ES.”
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.